1. Home
  2. RDFN vs ELVN Comparison

RDFN vs ELVN Comparison

Compare RDFN & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDFN
  • ELVN
  • Stock Information
  • Founded
  • RDFN 2002
  • ELVN 2016
  • Country
  • RDFN United States
  • ELVN United States
  • Employees
  • RDFN N/A
  • ELVN N/A
  • Industry
  • RDFN Real Estate
  • ELVN Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDFN Finance
  • ELVN Health Care
  • Exchange
  • RDFN Nasdaq
  • ELVN Nasdaq
  • Market Cap
  • RDFN 1.1B
  • ELVN 1.1B
  • IPO Year
  • RDFN 2017
  • ELVN 2020
  • Fundamental
  • Price
  • RDFN $7.69
  • ELVN $21.47
  • Analyst Decision
  • RDFN Hold
  • ELVN Strong Buy
  • Analyst Count
  • RDFN 11
  • ELVN 5
  • Target Price
  • RDFN $9.43
  • ELVN $37.80
  • AVG Volume (30 Days)
  • RDFN 4.3M
  • ELVN 248.6K
  • Earning Date
  • RDFN 02-25-2025
  • ELVN 03-13-2025
  • Dividend Yield
  • RDFN N/A
  • ELVN N/A
  • EPS Growth
  • RDFN N/A
  • ELVN N/A
  • EPS
  • RDFN N/A
  • ELVN N/A
  • Revenue
  • RDFN $1,016,774,000.00
  • ELVN N/A
  • Revenue This Year
  • RDFN $8.63
  • ELVN N/A
  • Revenue Next Year
  • RDFN $9.90
  • ELVN N/A
  • P/E Ratio
  • RDFN N/A
  • ELVN N/A
  • Revenue Growth
  • RDFN 3.70
  • ELVN N/A
  • 52 Week Low
  • RDFN $5.10
  • ELVN $10.90
  • 52 Week High
  • RDFN $15.29
  • ELVN $30.03
  • Technical
  • Relative Strength Index (RSI)
  • RDFN 41.16
  • ELVN 42.14
  • Support Level
  • RDFN $7.59
  • ELVN $20.16
  • Resistance Level
  • RDFN $8.18
  • ELVN $23.08
  • Average True Range (ATR)
  • RDFN 0.42
  • ELVN 1.60
  • MACD
  • RDFN 0.04
  • ELVN -0.09
  • Stochastic Oscillator
  • RDFN 51.77
  • ELVN 25.14

About RDFN Redfin Corporation

Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments and three reportable segments, real estate services, rentals, and mortgage. The company generates the majority of its revenue from Real estate services.

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Share on Social Networks: